Novel immunotherapeutic approaches for allergy and asthma.
about
Nanoparticulate adjuvants and delivery systems for allergen immunotherapyHuman dendritic cell DC-SIGN and TLR-2 mediate complementary immune regulatory activities in response to Lactobacillus rhamnosus JB-1.Amelioration of ovalbumin-induced allergic airway disease following Der p 1 peptide immunotherapy is not associated with induction of IL-35.
P2860
Novel immunotherapeutic approaches for allergy and asthma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Novel immunotherapeutic approaches for allergy and asthma.
@en
Novel immunotherapeutic approaches for allergy and asthma.
@nl
type
label
Novel immunotherapeutic approaches for allergy and asthma.
@en
Novel immunotherapeutic approaches for allergy and asthma.
@nl
prefLabel
Novel immunotherapeutic approaches for allergy and asthma.
@en
Novel immunotherapeutic approaches for allergy and asthma.
@nl
P2093
P2860
P1433
P1476
Novel immunotherapeutic approaches for allergy and asthma.
@en
P2093
Liam O'Mahony
Mubeccel Akdis
Reto Crameri
P2860
P304
P356
10.3109/08916931003674725
P577
2010-11-01T00:00:00Z